Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW, Nuche-Berenguer B, Jensen RT.
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):38-47. doi: 10.1097/MED.0000000000000218.
Vasoactive Intestinal Peptide-Secreting Tumors: A Review.
Siddappa PK, Vege SS.
Pancreas. 2019 Oct;48(9):1119-1125. doi: 10.1097/MPA.0000000000001402.
The role of vasoactive intestinal peptide in pulmonary diseases.
Zhong HL, Li PZ, Li D, Guan CX, Zhou Y.
Life Sci. 2023 Nov 1;332:122121. doi: 10.1016/j.lfs.2023.122121. Epub 2023 Sep 22.
Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice.
Kittikulsuth W, Nakano D, Kitada K, Uyama T, Ueda N, Asano E, Okano K, Matsuda Y, Nishiyama A.
Sci Rep. 2023 Jan 17;13(1):927. doi: 10.1038/s41598-023-28073-6.
Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.
Sallicandro L, Gliozheni E, Feudi D, Sabbatini P, Pellegrino RM, Alabed HBR, Baldini D, Gerli S, Alviggi C, Cascardi E, Cicinelli E, Malvasi A, Fioretti B.
Front Endocrinol (Lausanne). 2024 May 7;15:1331282. doi: 10.3389/fendo.2024.1331282. eCollection 2024.
Vasoactive intestinal peptide.
Said SI.
J Endocrinol Invest. 1986 Apr;9(2):191-200. doi: 10.1007/BF03348097.
Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery.
Klippstein R, Pozo D.
Adv Protein Chem Struct Biol. 2015;98:145-68. doi: 10.1016/bs.apcsb.2014.11.006. Epub 2015 Mar 3.
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, Zaidi MY, Zhu J, Cardenas M, Liu Y, Gumber S, Robinson B, Sen-Majumdar A, Zhang H, Chandrakasan S, Kissick H, Frey AB, Thomas SN, El-Rayes BF, Lesinski GB, Waller EK.
Nat Commun. 2022 Oct 27;13(1):6418. doi: 10.1038/s41467-022-34242-4.
Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway.
Asano S, Ono A, Sakamoto K, Hayata-Takano A, Nakazawa T, Tanimoto K, Hashimoto H, Ago Y.
Peptides. 2023 Mar;161:170940. doi: 10.1016/j.peptides.2023.170940. Epub 2023 Jan 2.
Pre-clinical study on tumor vasoactive intestinal peptide receptor scintigraphy.
Wang X, Zhang M, Yang Z, Lin B, Zhang Q.
Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):331-4.
